{"prompt": "['Alliance A221701', 'outcome measures used in the repeated-measures (means) mixed model are the serially', 'measured patient-reported mouth pain scores obtained at baseline and daily during the eight', 'week study period. The covariates included in the model are indicator variables for all', 'assessment time points, an indicator for the treatment approach (initial dexamethasone; initial', 'placebo), and the corresponding two-way interaction terms. This macro will rerun the primary', 'analyses with each alternative approach to imputation to demonstrate the veracity of the results', 'in the presence of missing data. This analytic approach to compare the prevention approach VS', 'early treatment approach will maintain the ITT principle and allow for missing data (i.e. under', 'the reasonable assumption of missing at random). Furthermore, it has been shown that this', 'analytic approach is superior to a simple AUC summary measure in terms of both bias and', 'precision in the presence of missing data34. In this supplemental analysis, we will also account', 'for the two stratification factors in the model, as well as potentially other baseline covariates.', 'To maintain the 5% significance level, this statistical test will only be performed if the first', 'primary endpoint is met.', '49', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '13.11 Inclusion of Women and Minorities', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial Categories', 'Not Hispanic or Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/', '1', '1', '1', '1', '4', 'Alaska Native', 'Asian', '1', '1', '1', '1', '4', 'Native Hawaiian or', 'Other Pacific', '1', '1', '1', '1', '4', 'Islander', 'Black or African', '20', '5', '3', '1', '29', 'American', 'White', '177', '41', '13', '3', '234', 'More Than One', '1', '1', '1', '1', '4', 'Race', 'Total', '201', '50', '20', '8', '279', 'Ethnic Categories:', 'Hispanic or Latino - a person of Cuban, Mexican, Puerto Rican, South or Central', 'American, or other Spanish culture or origin, regardless of race. The term \"Spanish', 'origin\" can also be used in addition to \"Hispanic or Latino.\"', 'Not Hispanic or Latino', 'Racial Categories', 'American Indian or Alaskan Native - a person having origins in any of the original', 'peoples of North, Central, or South America, and who maintains tribal affiliations or', 'community attachment.', 'Asian - a person having origins in any of the original peoples of the Far East, Southeast', 'Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan,', 'Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (Note:', 'Individuals from the Philippine Islands have been recorded as Pacific Islanders in', 'previous data collection strategies.)', 'Black or African American - a person having origins in any of the black racial groups', 'of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to \"Black or', \"African American.'\", 'Native Hawaiian or other Pacific Islander - a person having origins in any of the original', 'peoples of Hawaii, Guam, Samoa, or other Pacific Islands.', 'White - a person having origins in any of the original peoples of Europe, the Middle', 'East, or North Africa.', '50', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '14.0 CORRELATIVE AND COMPANION STUDIES', 'There will be 2 substudies and all patients are encouraged to participate.', '14.1 Pharmacogenomics and Everolimus induced stomatitis A221701-ST1', '14.1.1 Background', 'The increased toxicity that has accompanied the everolimus plus exemestane therapy has', \"been the primary reason for patients' discontinuation of treatment. While some patients\", 'experience severe oral mTOR inhibitor-associated stomatitis (mlAS), others do not; this is', 'possibly due in part to genetic variability in genes that biotransform everolimus.', 'Everolimus is metabolized by CYP3A4, CYP3A5 and transported by p-glycoprotein. It', 'binds with high affinity to FK506 binding protein - -12 to form a complex that inhibits', 'mTOR activation and reduces activity of effectors downstream, blocking cell cycle', 'progression from G1 to S phase and leading to cell growth arrest and apoptosis. These', 'proteins are encoded by genes that are genetically polymorphic and whose activities result', 'in variability in the extent of metabolism of everolimus and variability in signaling', 'associated with the mTOR pathway-all of which might lead to variations in everolimus', 'sensitivity.', 'A recent next-generation sequencing study of tumor samples from patients identified', 'somatic mutations as genetic markers in mTOR signaling pathway (TSC1, TSC2, MTOR', 'alterations) to be associated with everolimus sensitivity 58 On the other hand, studies have', 'reported single nucleotide polymorphisms (SNPs) in genes involved in everolimus', 'pharmacokinetics and pharmacodynamics to be associated with everolimus clinical', 'outcomes with varying results. For example in two studies examining FGFR4 rs351855', 'SNP in neuroendocrine tumors, one reported no association with everolimus efficacy 44and', 'the other reported reduced sensitivity to everolimus and increased tumor progression 45', \"A recent review covering pharmacogenetics of mTOR inhibitors' role in the\", 'pharmacodynamics of immunosuppressive drugs, 46 it was highly recommended that 3', 'MTOR SNPs namely rs2024627, rs2295080, rs1883965 be investigated in studies as these', 'were associated with decreases in hemoglobin levels in solid organ transplantation.', 'In the only study to date exploring the impact of germline variation on exemestane-', 'everolimus outcome in 90 women with metastatic breast cancer, Pascual et al. (2017)4', 'reported that CYP3A4 rs35599367 was associated with higher concentrations of', 'everolimus in blood. The global minor allele frequency of the CYP3A4 rs35599367 SNP', 'is low, 0.015, however in Caucasians the frequency ranges from 0.03-0.05. In this study by', 'Pascual et al (2017), they found 4 patients with rs35599367 genotype out of 37 patients', 'who had PK data on day 14 of the first everolimus cycle and were able to associate the', 'genotype with plasma everolimus concentration levels. We will not genotype for the', 'CYP3A4 rs35599367 SNP in this study because of its low allele frequency. Polymorphisms', 'in CYP3A5 and CYP2C8 (everolimus metabolism) and in ABCBI (everolimus transport),', 'and also in genes belonging to the PI3K/AKT/mTOR pathway (FGFR4, PHLPP2, AKT2,', 'PIK3R1, RAPTOR, AKT) have also been evaluated for their association with everolimus', 'sensitivity. While SNPs in FGFR4, RAPTOR and PIK3RI were associated with toxicities', 'such as leucopenia, hyperglycemia and lymphopenia, only ABCBI rs1045642 SNP was', 'associated with mucositis47', 'Furthermore in a GWAS study evaluating everolimus sensitivity in lymphoblastic cell', 'lines, 48 showed that 10 SNPs (rs218869, rs7694207, rs10987149, rs 12932018, rs2702449,', 'rs16887552, rs2832270, rs1460196, rs4148330, rs13272072) were highly associated with', 'everolimus sensitivity (p=10-6 even though they did not reach the expected genome-wide', '51', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}